12/5
10:13 am
mura
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc [Yahoo! Finance]
Neutral
Report
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc [Yahoo! Finance]
12/5
07:45 am
mura
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
Neutral
Report
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
12/3
04:30 pm
mura
Mural Oncology Announces Sanction of the Scheme by the High Court
Neutral
Report
Mural Oncology Announces Sanction of the Scheme by the High Court
11/27
02:51 pm
mura
Mural Oncology (NASDAQ:MURA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Mural Oncology (NASDAQ:MURA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
09:00 am
mura
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
Medium
Report
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
11/21
02:03 pm
mura
Mural Oncology (NASDAQ:MURA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Mural Oncology (NASDAQ:MURA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/13
10:41 am
mura
Form 8.3 [Yahoo! Finance]
Low
Report
Form 8.3 [Yahoo! Finance]
11/7
07:07 pm
mura
Form 8.3 [Yahoo! Finance]
Low
Report
Form 8.3 [Yahoo! Finance]
10/31
01:04 pm
mura
Mural Oncology (NASDAQ:MURA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Mural Oncology (NASDAQ:MURA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/24
04:25 pm
mura
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
Low
Report
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
10/8
12:30 pm
mura
Mural Oncology (NASDAQ:MURA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Mural Oncology (NASDAQ:MURA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/29
02:39 pm
mura
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PHLT, ARIS, MURA on Behalf of Shareholders
Low
Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PHLT, ARIS, MURA on Behalf of Shareholders
9/23
08:24 pm
mura
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting [Yahoo! Finance]
Low
Report
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting [Yahoo! Finance]
9/23
07:52 pm
mura
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting
Neutral
Report
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting
9/23
01:51 pm
mura
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CBAN, HBI, NWE, MURA on Behalf of Shareholders
Neutral
Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CBAN, HBI, NWE, MURA on Behalf of Shareholders
9/22
05:30 pm
mura
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - GTLS, PHLT, ARIS, and MURA
Low
Report
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - GTLS, PHLT, ARIS, and MURA